Develops oral peptide tablets for patients with osteoporosis, hypoparathyroidism and metabolic disorders.
10-K for FY2025, filed Mar 27, 2026Entera is a clinical stage company focused on developing first-in-class oral tablet formats of peptides or protein replacement therapies.…View ↗
Our pipeline includes differentiated, first-in-class oral peptides targeting PTH(1-34), GLP-1/Glucagon and GLP-2:View ↗
Our most advanced product candidate, EB613 (oral teriparatide, or oral PTH[1-34]), is being developed as the first oral, osteoanabolic…View ↗
Our product candidate, EB612, is being developed as the first oral PTH(1-34) tablet peptide replacement therapy for patients with…View ↗
OXM is a naturally occurring GLP-1/Glucagon dual agonist peptide hormone found in the small intestine that acts to suppress appetite…View ↗
Revenue comes from research services under an agreement, with the services revenue counted over the agreement’s duration.
10-K for FY2025, filed Mar 27, 2026Revenues attributed to the research services agreement are recognized over the duration of the research services agreement.View ↗
$42K
10-K for FY2025, filed Mar 27, 2026
$42K ↗No. It lost $11.4M in FY2025.
Shrinking. Revenue fell 93% in 4 years, from $571K in FY2021 to $42K in FY2025, about 48% a year.
Broader peptide programs
The older report centers on oral PTH candidates and describes other peptides as early research; the latest details an oral metabolic-peptide collaboration and an oral tablet program for short bowel syndrome.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 27, 2026EB618 Program (Oral GLP-1/Glucagon)View ↗
In September 2023, we entered into a research collaboration agreement (the “2023 Collaboration Agreement”) with OPKO. Under the terms of…View ↗
Oral GLP-2View ↗
This program focuses on developing the first GLP-2 peptide tablet alternative for patients suffering from short bowel syndrome and…View ↗
Loading...